JHEP reports : innovation in hepatology · 2026
Platelet hyperactivation drives oxidized mitochondrial DNA-induced neutrophil extracellular traps formation in biliary atresia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tan Ledong, Ma Sige, Ye Rongchen, Shan Jiarou, Tong Yanlu, Ren Yixian, Meng Liuhong, Wang Zhe, Wen Zhe, Liu Fei, Guan Xisi, Liang Jiankun, Liang Qifeng, Xu Fuxing, Wen Ying, Zhang Ruizhong, Xia Huimin
Аннотация
BACKGROUND & AIMS: Biliary atresia (BA) is a progressive neonatal cholangiopathy characterized by unresolved inflammation and neutrophil extracellular traps (NET) formation. Although neutrophils contribute to bile duct injury, the upstream mechanisms driving their activation remain poorly defined. This study investigated whether platelet (PLT) hyperactivation promotes NET-mediated inflammation in BA and evaluated the therapeutic potential of targeting S100A8/A9.
METHODS: The role of PLT hyperactivation in neutrophil-mediated inflammation in BA was evaluated through retrospective clinical review, single-cell RNA sequencing, and cell coculture experiments. The therapeutic potential of paquinimod, a small-molecule inhibitor that blocks S100A8/A9 binding to Toll-like receptor 4 on PLT and thereby suppresses PLT activation, was evaluated in a murine model of BA.
RESULTS: Elevated PLT counts were observed in 54.2% (236/435) of patients with BA, and PLT hyperactivation (CD62p+) was increased in both patients and RRV-injected mice (p <0.0001). Single-cell analysis identified an expanded hyperactivated PLT subset enriched in proinflammatory pathways. Mechanistically, PLTs from patients with BA exhibited mitochondrial dysfunction and released oxidized mitochondrial DNA (ox-mtDNA), thereby promoting NET formation. An expanded population of S100+ neutrophils (47.0% vs. 14.3%, p <0.0001) expressing S100A8/A9 established a self-perpetuating inflammatory circuit that amplified PLTs activation and enhanced proinflammatory cytokine production (IL-1β, IL-6, tumor necrosis factor-alpha, p <0.001). In the murine model, treatment with paquinimod suppressed platelet activation, reduced hepatic NET formation, and significantly improved survival (83.3% vs. 0.0%, p <0.0001).
CONCLUSIONS: PLT hyperactivation drives ox-mtDNA-dependent NET formation and amplifies inflammatory signaling in BA. Pharmacological inhibition of S100A8/A9 with paquinimod attenuates disease progression in mice.
IMPACT AND IMPLICATIONS: Biliary atresia is a serious neonatal liver disease featuring bile duct inflammation and obstruction. Here, hyperactivated PLTs in biliary atresia patients released ox-mtDNA, triggering NET formation and exacerbating liver injury. Blocking the key inflammatory mediator S100A8/A9 with paquinimod reduced PLT activation and liver inflammation and improved survival in mice. These findings reveal a vicious immune cycle between PLTs and neutrophils and highlight novel treatment options for attenuating disease progression.
METHODS: The role of PLT hyperactivation in neutrophil-mediated inflammation in BA was evaluated through retrospective clinical review, single-cell RNA sequencing, and cell coculture experiments. The therapeutic potential of paquinimod, a small-molecule inhibitor that blocks S100A8/A9 binding to Toll-like receptor 4 on PLT and thereby suppresses PLT activation, was evaluated in a murine model of BA.
RESULTS: Elevated PLT counts were observed in 54.2% (236/435) of patients with BA, and PLT hyperactivation (CD62p+) was increased in both patients and RRV-injected mice (p <0.0001). Single-cell analysis identified an expanded hyperactivated PLT subset enriched in proinflammatory pathways. Mechanistically, PLTs from patients with BA exhibited mitochondrial dysfunction and released oxidized mitochondrial DNA (ox-mtDNA), thereby promoting NET formation. An expanded population of S100+ neutrophils (47.0% vs. 14.3%, p <0.0001) expressing S100A8/A9 established a self-perpetuating inflammatory circuit that amplified PLTs activation and enhanced proinflammatory cytokine production (IL-1β, IL-6, tumor necrosis factor-alpha, p <0.001). In the murine model, treatment with paquinimod suppressed platelet activation, reduced hepatic NET formation, and significantly improved survival (83.3% vs. 0.0%, p <0.0001).
CONCLUSIONS: PLT hyperactivation drives ox-mtDNA-dependent NET formation and amplifies inflammatory signaling in BA. Pharmacological inhibition of S100A8/A9 with paquinimod attenuates disease progression in mice.
IMPACT AND IMPLICATIONS: Biliary atresia is a serious neonatal liver disease featuring bile duct inflammation and obstruction. Here, hyperactivated PLTs in biliary atresia patients released ox-mtDNA, triggering NET formation and exacerbating liver injury. Blocking the key inflammatory mediator S100A8/A9 with paquinimod reduced PLT activation and liver inflammation and improved survival in mice. These findings reveal a vicious immune cycle between PLTs and neutrophils and highlight novel treatment options for attenuating disease progression.